FTC Chair Lina Khan stated that allowing such a merger would have created “a market that is less competitive and more susceptible to price manipulation.” Consumer advocacy groups had also argued that ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.